<DOC>
	<DOCNO>NCT02414516</DOCNO>
	<brief_summary>This Phase 1a , single center , open-label , repeat dose study evaluate safety , efficacy , Pharmacokinetics ascend dos OBP-801 patient advance solid tumor .</brief_summary>
	<brief_title>A Dose-Escalation Study OBP-801 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patient Inclusion Criteria Patients must meet follow inclusion criterion eligible enrollment study : Histologically cytologically confirm metastatic unresectable solid tumor . Has fail treatment standard therapy malignancy . Adequate Karnofsky Performance Status . An expected survival least 3 month . Adequate organ bone marrow function . Signed informed consent form study participation prior screen . Patient Exclusion Criteria Patients present follow exclude study : Clinically significant disease define protocol . Surgical therapy therapy within period define protocol . Any condition interfere compliance protocol determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HDAC</keyword>
	<keyword>Epigenetic</keyword>
	<keyword>Histone</keyword>
	<keyword>Acetylation</keyword>
</DOC>